Skip to main content
. 2022 Jun 3;12(1):325–334. doi: 10.1002/cam4.4854

FIGURE 3.

FIGURE 3

Progression‐free survival by modified RECIST with adjustment using inverse probability weighting. The Atez/Bev group showed better progression‐free survival (PFS) by modified RECIST as compared to the lenvatinib group after 0.5, 1, and 1.5 years (PFS rate: 56.6%/31.6%/non‐estimable (NE) vs. 48.6%/20.4%/11.2%, p < 0.0001).